Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00111
|
|||||
| Drug Name |
Posaconazole
|
|||||
| Synonyms |
Posaconazole; Noxafil; Sch 56592; Posaconazole SP; SCH56592; SCH-56592; UNII-6TK1G07BHZ; Schering 56592; CHEMBL1397; 6TK1G07BHZ; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Aspergillosis [ICD11: 1F20] | Approved | [1] | |||
| Therapeutic Class |
Antifungal Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C37H42F2N8O4
|
|||||
| Canonical SMILES |
CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
|
|||||
| InChI |
InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
|
|||||
| InChIKey |
RAGOYPUPXAKGKH-XAKZXMRKSA-N
|
|||||
| CAS Number |
CAS 171228-49-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 700.8 | Topological Polar Surface Area | 112 | ||
| Heavy Atom Count | 51 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 11 | |||
| XLogP |
4.6
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:64355
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Posaconazole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.